'Lightning struck': How a safety alert shifted doctor sentiment on Novartis' Beovu

Before, doctors believed Novartis’ new option offered better efficacy and an improved dosing schedule versus Regeneron’s Eylea, Raymond wrote.

“Then lightning struck,” he added. “The world changed with the ASRS communication regarding cases of occlusive vasculitis in Beovu treated patients.”